Paradigm Biopharmaceuticals Management
Management criteria checks 3/4
Paradigm Biopharmaceuticals' CEO is Paul Rennie, appointed in Jan 2014, has a tenure of 10.75 years. total yearly compensation is A$1.10M, comprised of 86.5% salary and 13.5% bonuses, including company stock and options. directly owns 2.65% of the company’s shares, worth €1.15M. The average tenure of the management team and the board of directors is 4.2 years and 4 years respectively.
Key information
Paul Rennie
Chief executive officer
AU$1.1m
Total compensation
| CEO salary percentage | 86.5% |
| CEO tenure | 10.8yrs |
| CEO ownership | 2.7% |
| Management average tenure | 4.2yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | AU$1m | AU$948k | -AU$59m |
| Mar 31 2024 | n/a | n/a | -AU$64m |
| Dec 31 2023 | n/a | n/a | -AU$69m |
| Sep 30 2023 | n/a | n/a | -AU$60m |
| Jun 30 2023 | AU$2m | AU$602k | -AU$52m |
| Mar 31 2023 | n/a | n/a | -AU$48m |
| Dec 31 2022 | n/a | n/a | -AU$44m |
| Sep 30 2022 | n/a | n/a | -AU$42m |
| Jun 30 2022 | AU$1m | AU$219k | -AU$39m |
| Mar 31 2022 | n/a | n/a | -AU$40m |
| Dec 31 2021 | n/a | n/a | -AU$41m |
| Sep 30 2021 | n/a | n/a | -AU$37m |
| Jun 30 2021 | AU$1m | AU$510k | -AU$34m |
| Mar 31 2021 | n/a | n/a | -AU$31m |
| Dec 31 2020 | n/a | n/a | -AU$28m |
| Sep 30 2020 | n/a | n/a | -AU$20m |
| Jun 30 2020 | AU$632k | AU$462k | -AU$12m |
| Mar 31 2020 | n/a | n/a | -AU$14m |
| Dec 31 2019 | n/a | n/a | -AU$16m |
| Sep 30 2019 | n/a | n/a | -AU$16m |
| Jun 30 2019 | AU$1m | AU$420k | -AU$16m |
| Mar 31 2019 | n/a | n/a | -AU$11m |
| Dec 31 2018 | n/a | n/a | -AU$7m |
| Sep 30 2018 | n/a | n/a | -AU$7m |
| Jun 30 2018 | AU$573k | AU$380k | -AU$6m |
Compensation vs Market: Paul's total compensation ($USD745.47K) is above average for companies of similar size in the German market ($USD501.82K).
Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.
CEO
Paul Rennie (65 yo)
10.8yrs
Tenure
AU$1,096,287
Compensation
Mr. Paul John Rennie, BSc, MBM, Grad Dip Commercial Law, MSTC, served as Independent Non-Executive Chairman at NeuroScientific Biopharmaceuticals Limited since June 21, 2021 until November 23, 2022, was it...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 10.8yrs | AU$1.10m | 2.65% A$ 1.2m | |
| Chief Medical Officer and Executive Director | 2.3yrs | AU$1.23m | 0.31% A$ 135.6k | |
| Company Secretary & CFO | 2.2yrs | no data | no data | |
| Chief Scientific Officer | 9.1yrs | no data | no data | |
| Director of Investor Relations | no data | no data | no data | |
| Global Head of Drug Safety & MPS | 4.3yrs | no data | no data | |
| Commercial Head | 4yrs | no data | no data | |
| Global Head of Regulatory Affairs | no data | no data | no data | |
| Global Clinical Head of OA | no data | no data | no data |
4.2yrs
Average Tenure
Experienced Management: P86's management team is considered experienced (4.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 10.4yrs | AU$1.10m | 2.65% A$ 1.2m | |
| Chief Medical Officer and Executive Director | 4.3yrs | AU$1.23m | 0.31% A$ 135.6k | |
| Independent & Non-Executive Director | 3.8yrs | AU$88.80k | no data | |
| Non-Executive Director | less than a year | AU$24.24k | 0.31% A$ 132.6k |
4.0yrs
Average Tenure
65yo
Average Age
Experienced Board: P86's board of directors are considered experienced (4 years average tenure).